Elbasvir + Grazoprevir 경구제(품명: 제파티어정)

· HEPATOLOGY. 7th Edition. 2016.

· Ferri's Clinical Advisor. 2017.

· Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease, Updated Edition. 2015.

· 2015 대한간학회 C형 간염 진료가이드라인. 2015.

· AASLD(American Association for the Study of the Liver Disease). 2016 July.

· EASL(European Association for the Study of the Liver) Recommendations on Treatment of Hepatitis C 2016.

· WHO Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version. 2016 April.

· APASL(The Asian-Pacific Association for the Study of the Liver). APASL consensus statements and recommendation on treatment of hepatitis C. 2016 April.

· Roth D, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-45.

· Zeuzem S, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Annals of internal medicine 2015;163:1-13.

· Lawitz E et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1075-86.

· Sulkowski M, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1087-97.

· Buti M, et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2016;62:32-6.

· Rockstroh JK, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The lancet HIV 2015;2:e319-27.

· NICE (2016.10.)

· CADTH (2016.5.)

· PBAC (2016.7.)

· Yokoyama O et al. (1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume.World J Urol. 2011 Apr;29(2):233-8.

· MOON KH. et al, A 12-Week, Open Label, Multi-Center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction in Patients with Neurogenic Bladder. Low Urin Tract Symptoms. 2015 Jan;7(1):27-31

· Osman NI et al. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol. 2015 May;33(5):697-706.

· Oelke M et al. Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014 Sep;13(9):1187-97.